BioSpace News Archive

Serenus.AI and HealthTrio are continuing an established partnership to launch an AI-based module to streamline and automate medical authorizations for knee replacements.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Evkeeza® (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH).

Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its licensee and distribution partner Nuance Pharma has launched its Bentrio nasal spray in Hong Kong.

Re-Vana Therapeutics Ltd, a privately-held specialty drug delivery company developing sustained-release therapeutics for the treatment of vision-threatening ocular diseases, today announced the closure of its Series A round with $11.9 million in funding, an oversubscription of $4 million.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that management will present at the Nasdaq 47th Investor Conference in London on Wednesday, December 7 at 8:30 a.m. EST/1:30 p.m. GMT.

NeuroPace, Inc today announced that the first patient with Lennox-Gastaut Syndrome (LGS) was treated in its feasibility investigational device exemption (IDE) study.

Experic , a contract development and manufacturing organization (CDMO) and clinical supply services company serving the biopharmaceutical industry, today announced the closing of a $14 million series B capitalization led by Harro Höfliger Packaging Systems, Inc. and East Seattle Partners.

Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced that the first participant has been dosed in an investigator-sponsored Phase 1 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with venetoclax (Venclexa®) in patients with relapsed or refractory acute myeloid leukemia (AML).

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conference on Wednesday, Dec. 7, 2022 at 8:00 a.m. ET (1:00 p.m. GMT).

Aziyo Biologics, Inc., a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, announced that it has commenced an underwritten public offering, subject to market and other conditions, of shares of its common stock.